EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease

Emilie K Mitten iD, Piero Portincasa iD, György Baffy iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27073241 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Emilie K Mitten und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a leading driver of hepatocellular carcinoma (HCC) worldwide. A substantial proportion of MASLD-related HCC arises in the noncirrhotic liver, highlighting critical gaps in current surveillance strategies that rely primarily on fibrosis stage to define risk. Although the annual incidence of HCC in noncirrhotic MASLD is low and does not justify universal surveillance, the extraordinary global prevalence of MASLD translates into a considerable absolute burden of cancer. Accumulating evidence demonstrates that HCC risk in MASLD is modulated not only by histologic severity but also by metabolic comorbidities, particularly type 2 diabetes mellitus, which can significantly amplify cancer risk even in pre-cirrhotic stages. From both clinical and health economic perspectives, these observations underscore the need for more complex and targeted surveillance approaches. This review synthesizes current epidemiologic data, metabolic and histologic modifiers of HCC risk, emerging biomarkers, and predictive models in MASLD, with a focus on noncirrhotic disease. We discuss how integrated, precision-based risk assessment may identify high-risk MASLD subgroups and enable targeted, cost-effective surveillance strategies to mitigate the growing burden of MASLD-associated HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularFatty LiverNon-alcoholic Fatty Liver DiseaseMetabolic DiseasesHumansRisk AssessmentRisk Factors

Stichwörter der Autor:innen

cluster analysishepatocarcinogenesismachine learningmetabolic burdennoncirrhoticsteatotic liver diseasesurveillance

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Division of Internal Medicine, Department of Precision and Regenerative Medicine, University 'Aldo Moro' Medical School, 70121 Bari, Italy.
  • Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Medicine, Section of Gastroenterology, VA Boston Healthcare System, 150 South Huntington Ave., Room 6A-46, Boston, MA 02130, USA.

ORCID-Profile: Emilie K Mitten, Piero Portincasa, György Baffy

Zitieren

APA

Mitten, E. K., Portincasa, P., & Baffy, G. (2026). Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073241

Vancouver

Mitten EK, Portincasa P, Baffy G. Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27073241

BibTeX
@article{Mitten2026,
  author = {Mitten, Emilie K and Portincasa, Piero and Baffy, György},
  title = {Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27073241}
}
Kostenlos starten →